Crimson Biopharm Inc.
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM) (NCT04933422) | Crimson Biopharm Inc. | 2027-01-01 |
Track Crimson Biopharm Inc. automatically
Every clearance here is in the API, with alerts when new ones post.